People with severe sickle cell disease (SCD) have reported significant improvements in their quality of life after receiving the approved gene-editing therapy Casgevy (exagamglogene autotemcel).

81.7% of patients were on an SGLT2 inhibitor 74.7% of patients were on an ARNI 95.1% of patients were on a beta-blocker 83.1% of patients were on an MRA Despite high use of GDMT, the rate of ...

Correctsequence Therapeutics’ experimental gene-editing therapy CS-101 has been used to treat a person with sickle cell disease (SCD) for the first time. Prior to treatment with CS-101, the patient — ...

The expansion of the manufacturing infrastructure in Israel, which is being led by the Ministry of Defense Directorate for R&D (DDRD) (MAFAT), will allow production of infrared solutions for advanced ...

This project demonstrates a comprehensive data warehousing and analytics solution, from building a data warehouse to generating actionable insights. Designed as a portfolio project, it highlights ...

We present an automatic and scalable text-to-SQL data synthesis framework, illustrated below: Building on SynSQL-2.5M, we introduce OmniSQL, a family of powerful text-to-SQL models available in three ...